Furthermore, targeting p300/CBP by small molecular inhibitors such as E7386 and A485 could remarkably enhance the efficacy of PD-L1 blockade therapy in prostate and breast cancers in preclinical mouse models (Liu J. et al., 2020; Yamada et al., 2021). The gene discussed is EP300; the disease is breast cancer.